Clinical Trial Update: Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis [Phase 2]

View source ↗

Summary

Phase 2 trial of bosentan for hepatopulmonary syndrome in patients with liver cirrhosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatopulmonary Syndrome
• Liver Cirrhosis

Drugs mentioned

• Bosentan (Bosentan)

Snippet

Sponsor: Medical University of Vienna | Conditions: Hepatopulmonary Syndrome, Liver Cirrhosis | Phase 2 | Status: TERMINATED